These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 23728349)

  • 1. Small-molecule inhibition of CBP/catenin interactions eliminates drug-resistant clones in acute lymphoblastic leukemia.
    Gang EJ; Hsieh YT; Pham J; Zhao Y; Nguyen C; Huantes S; Park E; Naing K; Klemm L; Swaminathan S; Conway EM; Pelus LM; Crispino J; Mullighan CG; McMillan M; Müschen M; Kahn M; Kim YM
    Oncogene; 2014 Apr; 33(17):2169-78. PubMed ID: 23728349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disruption of β-catenin/CBP signaling inhibits human airway epithelial-mesenchymal transition and repair.
    Moheimani F; Roth HM; Cross J; Reid AT; Shaheen F; Warner SM; Hirota JA; Kicic A; Hallstrand TS; Kahn M; Stick SM; Hansbro PM; Hackett TL; Knight DA
    Int J Biochem Cell Biol; 2015 Nov; 68():59-69. PubMed ID: 26315281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The gamma catenin/CBP complex maintains survivin transcription in β-catenin deficient/depleted cancer cells.
    Kim YM; Ma H; Oehler VG; Gang EJ; Nguyen C; Masiello D; Liu H; Zhao Y; Radich J; Kahn M
    Curr Cancer Drug Targets; 2011 Feb; 11(2):213-25. PubMed ID: 21158719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional and genomic analyses reveal therapeutic potential of targeting β-catenin/CBP activity in head and neck cancer.
    Kartha VK; Alamoud KA; Sadykov K; Nguyen BC; Laroche F; Feng H; Lee J; Pai SI; Varelas X; Egloff AM; Snyder-Cappione JE; Belkina AC; Bais MV; Monti S; Kukuruzinska MA
    Genome Med; 2018 Jul; 10(1):54. PubMed ID: 30029671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CBP/catenin antagonist safely eliminates drug-resistant leukemia-initiating cells.
    Zhao Y; Masiello D; McMillian M; Nguyen C; Wu Y; Melendez E; Smbatyan G; Kida A; He Y; Teo JL; Kahn M
    Oncogene; 2016 Jul; 35(28):3705-17. PubMed ID: 26657156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sam68 Allows Selective Targeting of Human Cancer Stem Cells.
    Benoit YD; Mitchell RR; Risueño RM; Orlando L; Tanasijevic B; Boyd AL; Aslostovar L; Salci KR; Shapovalova Z; Russell J; Eguchi M; Golubeva D; Graham M; Xenocostas A; Trus MR; Foley R; Leber B; Collins TJ; Bhatia M
    Cell Chem Biol; 2017 Jul; 24(7):833-844.e9. PubMed ID: 28648376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of Human Airway Epithelial Tissue Stem Cell Differentiation by β-Catenin, P300, and CBP.
    Malleske DT; Hayes D; Lallier SW; Hill CL; Reynolds SD
    Stem Cells; 2018 Dec; 36(12):1905-1916. PubMed ID: 30171668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential roles for the coactivators CBP and p300 on TCF/beta-catenin-mediated survivin gene expression.
    Ma H; Nguyen C; Lee KS; Kahn M
    Oncogene; 2005 May; 24(22):3619-31. PubMed ID: 15782138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma.
    Lin HH; Feng WC; Lu LC; Shao YY; Hsu CH; Cheng AL
    Cancer Lett; 2016 Oct; 381(1):58-66. PubMed ID: 27431312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wnt/β-catenin signalling induces MLL to create epigenetic changes in salivary gland tumours.
    Wend P; Fang L; Zhu Q; Schipper JH; Loddenkemper C; Kosel F; Brinkmann V; Eckert K; Hindersin S; Holland JD; Lehr S; Kahn M; Ziebold U; Birchmeier W
    EMBO J; 2013 Jul; 32(14):1977-89. PubMed ID: 23736260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Wnt/β-catenin and PI3K/Akt/mTOR pathways in T-cell acute lymphoblastic leukemia.
    Evangelisti C; Chiarini F; Cappellini A; Paganelli F; Fini M; Santi S; Martelli AM; Neri LM; Evangelisti C
    J Cell Physiol; 2020 Jun; 235(6):5413-5428. PubMed ID: 31904116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined inhibition of β-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo.
    Zhou H; Mak PY; Mu H; Mak DH; Zeng Z; Cortes J; Liu Q; Andreeff M; Carter BZ
    Leukemia; 2017 Oct; 31(10):2065-2074. PubMed ID: 28321124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interactions between β-catenin and transforming growth factor-β signaling pathways mediate epithelial-mesenchymal transition and are dependent on the transcriptional co-activator cAMP-response element-binding protein (CREB)-binding protein (CBP).
    Zhou B; Liu Y; Kahn M; Ann DK; Han A; Wang H; Nguyen C; Flodby P; Zhong Q; Krishnaveni MS; Liebler JM; Minoo P; Crandall ED; Borok Z
    J Biol Chem; 2012 Mar; 287(10):7026-38. PubMed ID: 22241478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safely targeting cancer stem cells via selective catenin coactivator antagonism.
    Lenz HJ; Kahn M
    Cancer Sci; 2014 Sep; 105(9):1087-92. PubMed ID: 24975284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of CREB binding protein-beta-catenin signaling down regulates CD133 expression and activates PP2A-PTEN signaling in tumor initiating liver cancer cells.
    Tang Y; Berlind J; Mavila N
    Cell Commun Signal; 2018 Mar; 16(1):9. PubMed ID: 29530069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The β-catenin/CBP-antagonist ICG-001 inhibits pediatric glioma tumorigenicity in a Wnt-independent manner.
    Wiese M; Walther N; Diederichs C; Schill F; Monecke S; Salinas G; Sturm D; Pfister SM; Dressel R; Johnsen SA; Kramm CM
    Oncotarget; 2017 Apr; 8(16):27300-27313. PubMed ID: 28460484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. E7386, a Selective Inhibitor of the Interaction between β-Catenin and CBP, Exerts Antitumor Activity in Tumor Models with Activated Canonical Wnt Signaling.
    Yamada K; Hori Y; Inoue S; Yamamoto Y; Iso K; Kamiyama H; Yamaguchi A; Kimura T; Uesugi M; Ito J; Matsuki M; Nakamoto K; Harada H; Yoneda N; Takemura A; Kushida I; Wakayama N; Kubara K; Kato Y; Semba T; Yokoi A; Matsukura M; Odagami T; Iwata M; Tsuruoka A; Uenaka T; Matsui J; Matsushima T; Nomoto K; Kouji H; Owa T; Funahashi Y; Ozawa Y
    Cancer Res; 2021 Feb; 81(4):1052-1062. PubMed ID: 33408116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ICG-001 suppresses growth of gastric cancer cells and reduces chemoresistance of cancer stem cell-like population.
    Liu Y; Chen H; Zheng P; Zheng Y; Luo Q; Xie G; Ma Y; Shen L
    J Exp Clin Cancer Res; 2017 Sep; 36(1):125. PubMed ID: 28893318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The CREB-binding protein inhibitor ICG-001 suppresses pancreatic cancer growth.
    Arensman MD; Telesca D; Lay AR; Kershaw KM; Wu N; Donahue TR; Dawson DW
    Mol Cancer Ther; 2014 Oct; 13(10):2303-14. PubMed ID: 25082960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of Imatinib Resistant CML Leukemic Stem/Initiating Cells and Their Sensitivity to CBP/Catenin Antagonists.
    Zhao Y; Wu K; Wu Y; Melendez E; Smbatyan G; Massiello D; Kahn M
    Curr Mol Pharmacol; 2018; 11(2):113-121. PubMed ID: 28933312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.